Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum β-lactamases

被引:22
作者
Babini, GS
Yuan, MF
Hall, LMC
Livermore, DM
机构
[1] Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England
[2] Barts & London Sch Med & Dent, London E1 2AD, England
关键词
piperacillin/tazobactam; Klebsiella; extended-spectrum beta-lactamases;
D O I
10.1093/jac/dkg114
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
MICs of piperacillin/tazobactam are conventionally determined by varying the concentration of piperacillin in the presence of a fixed 4 mg/L tazobactam. When tested in this way, the MIC distribution for Klebsiella isolates with extended-spectrum beta-lactamases (ESBLs) is strongly bimodal, such that many producers are inhibited at 16 + 4 mg/L whilst others require MICs of greater than or equal to512 + 4 mg/L. When, however, piperacillin/tazobactam was tested as a fixed 8:1 ratio, the MIC distribution became unimodal. If clavulanate 4 mg/L was combined with piperacillin, a unimodal MIC distribution was seen for ESBL-producing Klebsiella spp. but a bimodal distribution arose if the clavulanate concentration was reduced to 0.25 mg/L. These data for alternative combinations suggested that the bimodal MIC distribution seen for piperacillin + tazobactam 4 mg/L was a titration effect, not a reflection of some ESBLs being resistant to tazobactam. Even within single strains, as defined by serotype and DNA fingerprints, there was considerable variation in susceptibility to piperacillin + tazobactam 4 mg/L, with some representatives highly susceptible and others highly resistant. Some of the more resistant representatives produced more of their ESBL, or had a greater number of beta-lactamase types, but these associations were not universal. Elevated resistance to piperacillin + tazobactam was not associated with porin change in any ESBL producer examined, but has been found by others.
引用
收藏
页码:605 / 612
页数:8
相关论文
共 21 条
[1]   MOLECULAR EPIDEMIOLOGY OF KLEBSIELLA-PNEUMONIAE STRAINS THAT PRODUCE SHV-4 BETA-LACTAMASE AND WHICH WERE ISOLATED IN 14 FRENCH HOSPITALS [J].
ARLET, G ;
ROUVEAU, M ;
CASIN, I ;
BOUVET, PJM ;
LAGRANGE, PH ;
PHILIPPON, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (10) :2553-2558
[2]   Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998 [J].
Babini, GS ;
Livermore, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) :183-189
[3]   DISSEMINATION IN 5 FRENCH HOSPITALS OF KLEBSIELLA-PNEUMONIAE SEROTYPE-K25 HARBORING A NEW TRANSFERABLE ENZYMATIC RESISTANCE TO 3RD GENERATION CEPHALOSPORINS AND AZTREONAM [J].
BURE, A ;
LEGRAND, P ;
ARLET, G ;
JARLIER, V ;
PAUL, G ;
PHILIPPON, A .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1988, 7 (06) :780-782
[4]   A FUNCTIONAL CLASSIFICATION SCHEME FOR BETA-LACTAMASES AND ITS CORRELATION WITH MOLECULAR-STRUCTURE [J].
BUSH, K ;
JACOBY, GA ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1211-1233
[5]   ACTIVITY OF CEFEPIME AND OTHER BETA-LACTAM ANTIBIOTICS AGAINST PERMEABILITY MUTANTS OF ESCHERICHIA-COLI AND KLEBSIELLA-PNEUMONIAE [J].
CHEN, HY ;
LIVERMORE, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :63-74
[6]   Complexity and diversity of Klebsiella pneumoniae strains with extended-spectrum β-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa [J].
Essack, SY ;
Hall, LMC ;
Pillay, DG ;
McFadyen, ML ;
Livermore, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :88-95
[8]   SELECTION AND CHARACTERIZATION OF BETA-LACTAM-RESISTANT ESCHERICHIA-COLI K-12-MUTANTS [J].
JAFFE, A ;
CHABBERT, YA ;
DERLOT, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (04) :622-625
[9]   DIFFERENT RATIOS OF THE PIPERACILLIN-TAZOBACTAM COMBINATION FOR TREATMENT OF EXPERIMENTAL MENINGITIS DUE TO KLEBSIELLA-PNEUMONIAE PRODUCING THE TEM-3 EXTENDED-SPECTRUM BETA-LACTAMASE [J].
LELEU, G ;
KITZIS, MD ;
VALLOIS, JM ;
GUTMANN, L ;
DECAZES, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (02) :195-199
[10]  
Livermore D.M., 1996, ANTIBIOTICS LAB MED, P502